Using a Leishmania Vaccine immunogen saliva of the sand Fly. Methods.

摘要

Item 1: vaccine ingredients, characterized by: (a) an expression medium, in which the medium includes a polynucleotide, which encodes one or more meters of polypeptide selected from a group, including a saliva. Longipalpis, a variant or Lu's saliva (b) Acceptable for use in veterinary or pharmacologically acceptable vehicles, thinners, or precursors. ILO Convention No. 2: the vaccine of Convention No. 1 is characterized by that the expression vectors are selected from pvr2001-topo, pvr2001-topa, pvr1020, pvr1012, pab110, ALVAC and trovac,MVA and baculovirus. Requirement 5: the vaccine required in requirement 1 is characterized by at least 70% sequence characteristics of polynucleotide and one polynucleotide, and its sequence is in SEQ ID n: 2, 4, 6, 8, 12, 14, 16, 18, 21, 22, 89, 90 or 91. Item 13: composition of the vaccine, which is characterized by: (a) a glucose saliva. Lobster, a variant, or a piece of Lu's saliva (b) Acceptable for use in veterinary or pharmacologically acceptable vehicles, thinners, or precursors. Requirement 15: any required vaccineThe ADEM s vaccine is characterized by at least one leishmaniasis antibody. 1. Claim 18: a vehicle, characterized by including one or more polynucleotide selected from the group, which is composed of the following: (a) a polynucleotide, which encodes a polynucleotide, which has at least 80% sequence characteristics, and has a polynucleotide, whose sequence is contained in SEQ ID n: 1, 5, 3, 7, 11, 13, 15 or 17; (b) A polynucleotide, having at least 70% polynucleotide sequence characteristics, which encodes a polynucleotide, the sequence of which is the same as that of SEQ ID n: 1, 3, 5, 7, 11, 13, 15 or 17;(c) A polynucleotide having sequence characteristics of at least 70%, the sequence of which is consistent with the sequence listed in SEQ ID n: 2, 4, 6, 8, 12, 14, 16, 18, 21, 22, 89, 90 or 91; in this sequence, the vector is a living expression vector or in vitro expression vector. Request No. 19: the vector of request No. 18, which is characterized by the vector of Bacillus. Requirement No. 22: a useless mobile phone, characterized by that it has been transformed into the vector of requirement No. 18. Request 31 for an isolated PVCcharacterized in that said polynucleotide comprises: a) a nucleotide sequence having at least 70% sequence identity with a polynucleotide having the sequence indicated in SEQ ID Nø: 2, 4, 6, 8, 12, 14, 16 , 18, 21, 22, 89, 90 or 91; b) a nucleotide sequence encoding a polypeptide having at least 80% sequence identity with a polypeptide having the sequence indicated in SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 or 17 ; or c) a polynucleotide having at least 70% sequence identity with a polynucleotide encoding a polypeptide having the sequence indicated in SEQ ID Nø: 1, 3, 5, 7, 11, 13,15 or 17 Requirement 34: a salivary moth of Lu. a. Basically pure longipalpis, which is characterized in that the polyurethane comprises: (a) a series of carbamates containing at least 80% of the polyurethane sequence, the sequence of which is the same as that specified in SEQ ID n: 1, 5, 3, 7, 11, 13, 15 or 17; (b) 1, 3, 5, 7, 11, 13, 15 or 17; (c) an immune fragment consisting of at least 8 consecutive carbamates in the sequence of 1, 5, 3, 13, 15 or 17,which specifically binds to an antibody that specifically binds to the amino acid sequence indicated in SEQ ID No: 1, 3, 5, 7, 11, 13, 15 or 17; or d) an amino acid sequence indicated in SEQ ID Nø: 1, 3, 5, 7, 11, 13, 15 or 17, and where administration of the polypeptide to a subject produces an immune response against Lu. Longipalpis Claim 37: An antibody, characterized in that it specifically binds to the polypeptide of claim 34.